Zibotentan
Sponsors
Astrazeneca AB, Cardiff University, University College, London, NHS Greater Glasgow and Clyde, AstraZeneca
Conditions
Chronic Kidney DiseaseChronic Kidney DiseasesCirrhosis of the liver is a condition in which the liver is scarred and damagedColorectal CancerHealthy Female ParticipantsHepatic ImpairmentLiver CirrhosisLiver cirrhosis with features of portal hypertension.
Phase 1
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
CompletedNCT05112419
Start: 2021-11-10End: 2021-12-15Updated: 2022-01-27
Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
CompletedNCT05505162
Start: 2022-08-24End: 2023-01-10Updated: 2023-02-09
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
CompletedNCT06715670
Start: 2024-12-05End: 2025-02-28Updated: 2025-12-04
Phase 2
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
CompletedNCT01205711
Start: 2010-04-30End: 2012-09-30Updated: 2014-07-08
Zibotentan Better Renal Scleroderma Outcome Study
CompletedNCT02047708
Start: 2014-10-31End: 2017-10-31Updated: 2017-10-31
Precision Medicine With Zibotentan in Microvascular Angina
CompletedNCT04097314
Start: 2019-10-18End: 2023-06-08Updated: 2023-08-04
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
CompletedNCT04724837
Start: 2021-04-28End: 2023-06-01Updated: 2024-07-30
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
CompletedNCT05570305
Start: 2022-10-06End: 2025-03-05Updated: 2025-04-30
A Two Part Phase IIa/b Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Dose ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension
CompletedCTIS2023-505405-17-00
Start: 2022-10-07End: 2025-07-17Target: 111Updated: 2025-02-07
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy as well as Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis
CompletedCTIS2023-506893-11-00
Start: 2024-04-19End: 2024-12-09Target: 36Updated: 2024-12-11